- Home
- LGCY vs SLS Comparison
LGCY vs SLS Comparison
Compare LGCY & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LGCY
- SLS
- Stock Information
- Founded
- LGCY 2009
- SLS 2012
- Country
- LGCY United States
- SLS United States
- Employees
- LGCY N/A
- SLS N/A
- Industry
- LGCY
- SLS Biotechnology: Pharmaceutical Preparations
- Sector
- LGCY
- SLS Health Care
- Exchange
- LGCY NYSE
- SLS Nasdaq
- Market Cap
- LGCY 67.3M
- SLS 75.3M
- IPO Year
- LGCY 2024
- SLS N/A
- Fundamental
- Price
- LGCY $5.77
- SLS $1.32
- Analyst Decision
- LGCY Strong Buy
- SLS Buy
- Analyst Count
- LGCY 2
- SLS 1
- Target Price
- LGCY $8.48
- SLS $3.00
- AVG Volume (30 Days)
- LGCY 65.8K
- SLS 753.9K
- Earning Date
- LGCY 11-14-2024
- SLS 11-13-2024
- Dividend Yield
- LGCY N/A
- SLS N/A
- EPS Growth
- LGCY 90.87
- SLS N/A
- EPS
- LGCY 0.63
- SLS N/A
- Revenue
- LGCY $49,638,473.00
- SLS N/A
- Revenue This Year
- LGCY N/A
- SLS N/A
- Revenue Next Year
- LGCY N/A
- SLS N/A
- P/E Ratio
- LGCY $10.34
- SLS N/A
- Revenue Growth
- LGCY 32.36
- SLS N/A
- 52 Week Low
- LGCY $3.60
- SLS $0.50
- 52 Week High
- LGCY $7.83
- SLS $1.72
- Technical
- Relative Strength Index (RSI)
- LGCY N/A
- SLS 60.02
- Support Level
- LGCY N/A
- SLS $1.22
- Resistance Level
- LGCY N/A
- SLS $1.39
- Average True Range (ATR)
- LGCY 0.00
- SLS 0.08
- MACD
- LGCY 0.00
- SLS 0.02
- Stochastic Oscillator
- LGCY 0.00
- SLS 72.00
About LGCY LEGACY EDUCATION INC
Legacy Education Inc is engaged in career-focused, post-secondary education services to students at all stages of adult life, from recent high school graduates to working parents.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.